Clinical Trial Update: Pharmacodynamic EffIcacy and Clinical Benefit of AT 007 in Patients With Sorbitol Dehydrogenase (SORD) Deficiency [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 clinical trial update evaluating AT 007 in patients with hereditary neuropathy caused by sorbitol dehydrogenase (SORD) deficiency, reporting pha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Neuropathy Caused By Sorbitol Dehydrogenase Deficiency

Drugs mentioned

• AT 007

Snippet

Sponsor: Applied Therapeutics, Inc. | Conditions: Hereditary Neuropathy Caused by SORD Deficiency | Phase 2, Phase 3 | Status: ACTIVE_NOT_RECRUITING